Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTR3A | P46098 | 7/20 | 0.45 |
| ▸ | CNR2 | P34972 | 5/20 | 0.44 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | ELANE | P08246 | 2/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM6A | O15550 | 1/20 | 0.41 |
| ▸ | TET3 | O43151 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.41 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3534671 | 0.99 | HTR3A (0.44) | KDM4EHTR3ACNR2CNR1ELANE | |
| SCHEMBL3534667 | 0.88 | HTR3A (0.47) | HTR3ACNR2CNR1ELANEATM | |
| SCHEMBL7396445 | 0.84 | CNR1 (0.49) | CNR2CNR1 | |
| SCHEMBL6223291 | 0.81 | HTR3A (0.39) | HTR3ACNR2CNR1ELANE | |
| SCHEMBL8692020 | 0.80 | CNR1 (0.50) | KDM4ECNR2CNR1ATMKDM6B | |
| SCHEMBL3540199 | 0.80 | CNR1 (0.53) | HTR3ACNR2CNR1ELANE | |
| SCHEMBL28146834 | 0.79 | KDM4E (0.48) | KDM4EHTR3ACNR2CNR1ATM | |
| SCHEMBL24437278 | 0.78 | PDE6D (0.45) | KDM4ECNR2CNR1KDM6BKDM6A | |
| SCHEMBL1606716 | 0.78 | NPC1 (0.49) | KDM4ECNR2CNR1ELANEL3MBTL1 | |
| SCHEMBL27521014 | 0.78 | ELANE (0.41) | HTR3ACNR2CNR1ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459938-B2 | ORAI channel inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
| US-7683074-B2 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-7419987-B2 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | ELBION AG (DE) | 2008-09-02 | — | — | US | disclosed |
| US-20080207680-A1 | 7-Azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| US-7169787-B2 | 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | ELBION AG (DE) | 2007-01-30 | — | — | US | disclosed |
| US-20060258700-A1 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | BIOTIE THERAPIES GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| EP-1330455-B1 | NOVEL 7-AZAINDOLES, USE THEREOF AS PHOSPHODIESTERASE 4 INHIBITORS AND METHOD FOR PRODUCING THE SAME | ELBION AG (DE) | 2005-08-03 | — | — | EP | disclosed |
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | BIOTIE THERAPIES GMBH (DE) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106641-A1 | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | PDE4A, PDE4B, PDE4C | KDM4E 155/4885HTR3A 862/4885CNR2 2555/4885 |
| US-12459938-B2 | ORAI channel inhibitors | ORAI1, CACNA1E, ORAI3 | KDM4E 1740/4885HTR3A 1530/4885CNR2 209/4885 |
| US-20060258700-A1 | 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | PDE4A, PDE4B, PDE3A | KDM4E 161/4885HTR3A 578/4885CNR2 3086/4885 |
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | KDM4E 2818/4885HTR3A 2385/4885CNR2 745/4885 |
| US-20080207680-A1 | 7-Azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them | PDE4A, PDE4B, PDE7A | KDM4E 184/4885HTR3A 887/4885CNR2 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.